MIAMI, Oct. 2, 2019 /PRNewswire/ — ArisGlobal, the visionary provider of drug development technology for the life sciences industry, today announced the availability of LifeSphere® MultiVigilance 10 (LSMV10), the industry’s only end-to-end drug safety system with production-ready automation. LSMV10 has been developed and tested in partnership with leading global pharmaceutical companies and health authorities, resulting in a solution that provides immediate efficiency gains and out-of-the-box compliance with all global submission requirements.
Under tightening budgets and evolving global regulations, safety case volumes continue to grow by nearly 15% each year, creating challenges for today’s drug safety teams. To address these pressures, LSMV10 leverages cognitive computing technologies such as natural language processing and machine learning, providing a single, global database that supports end-to-end automation of all adverse event processing. In addition, LSMV10 is part of ArisGlobal’s unified LifeSphere® Platform and is the first and only safety system to offer out-of-the-box integration with medical information and product complaint solutions, enabling the seamless exchange of safety data between these critical functions.
“Since we launched LifeSphere’s initial AI capabilities in June 2018, we’ve been fortunate to work with an incredible group of industry-leading early adopters who have helped us make significant advancements in PV automation” said Aman Wasan, Vice President of Global Pharmacovigilance at ArisGlobal. “The result is production-ready automation in LSMV10, extensively tested and used by the world’s leading regulatory agency and several large life sciences organizations, including two of the top 25 pharma. This group worked with us to identify automation opportunities within case processing and assisted in developing innovative ways to solve them. This has resulted in significant efficiency gains and the potential for sizable cost savings.”
The foundation of ArisGlobal’s all new LifeSphere Safety platform, LifeSphere MultiVigilance 10 has been built from the ground up on brand new cloud architecture, powered by Amazon Web Services. Seamless upgrades delivered over the cloud ensure that LSMV10 is always “future proofed” and compliant, and customers no longer need to manage expensive and resource-intensive on-premise solutions.
Learn more: For more on LifeSphere® Multivigilance 10, visit: https://www.arisglobal.com/products/LSMV10/
About ArisGlobal
ArisGlobal is a visionary technology company that’s transforming the way today’s most successful life sciences companies develop breakthroughs and bring new products to market. The ArisGlobal LifeSphere® cognitive technology platform integrates machine-learning capabilities to automate the core functions of the product lifecycle. Designed with deep expertise and a long-term perspective that spans more than 30 years, our cognitive platform delivers actionable insights, boosts efficiency, ensures compliance, and lowers total cost of ownership through multi-tenancy.
Headquartered in the United States, ArisGlobal has regional offices in Europe, India, Japan and China.
Visit arisglobal.com or follow ArisGlobal on LinkedIn and Twitter.
Contact:
Alberto Cantor
Senior Manager, Corporate Marketing
acantor@arisglobal.com
+1-609-360-4042
Source: ArisGlobal
Logo – http://mma.prnewswire.com/media/523994/ArisGlobal_Logo.jpg
View original content to download multimedia:http://www.prnewswire.com/news-releases/arisglobal-announces-lifesphere-multivigilance-10-industrys-first-end-to-end-safety-system-with-production-ready-automation-300925875.html
SOURCE ArisGlobal
Charlotte, North Carolina--(Newsfile Corp. - December 23, 2024) - cbdMD, Inc. (NYSE American: YCBD) (NYSE…
AUSTIN, TEXAS / ACCESSWIRE / December 23, 2024 / Interactive Strength Inc. (Nasdaq:TRNR) ("TRNR" or…
Originally published in Quest Diagnostics' 2023 Corporate Responsibility ReportNORTHAMPTON, MA / ACCESSWIRE / December 23,…
Marlborough, Massachusetts--(Newsfile Corp. - December 23, 2024) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO), a clinical-stage…
WESTON, Fla.--(BUSINESS WIRE)--ILiAD Biotechnologies, LLC (ILiAD), a clinical stage biotech company developing the world’s most…
WESTON, Fla.--(BUSINESS WIRE)--ILiAD Biotechnologies, LLC (ILiAD), a clinical stage biotech company developing the world’s most…